New Ovarian Cancer Biotech Pipeline

Perusing the latest from several sources.... I thought I'd post a list of biotech meds in development at various stages of clinical trials as of December 2008. Some are specific to ovarian cancer, others are being tested in several areas, and some include Fallopian tube and primary peritoneal cancers which are certainly treated in a very similar way. After the listing are phone numbers you can call for more info, where available.

AMG386 from Amgen is a recombinant fusion protein in Phase II (805)447-1000

Avastin from Genetech is a monoclonal Ab in Phase III (650)225-1000

DCVax-L from Northwest Bio is a dendritic cell vaccine in Phase I/II (240)497-9024

EGEN-001 from Expression Genetics is an interleukin in Phase I (256)512-0077

Herceptin from Genentech is a monclonal antibody in Phase II (650)225-1000

IL-21 from Zymogenetics is an interleukin in Phase I/II (206)442-6600

IMT-1012 from Immunotrope is an immunotherapeutic vaccine in Phase I (215)253-4180

Advexin from Introgen Therapeutics is in the gene therapy arena Phase I (512)708-9310

Neuvenge from Dendreon is a dendritic cell vaccine in Phase I (206) 256-4545

OmniTarg from Genentech is a monoclonal antibody going to Phase III (650) 225-1000

OvaRex from ViRexx is a monoclonal antibody in Phase III (780) 433-4411

Ovax from AVAX is a vaccine in Phase I/II (215) 241-9760

Tucotuzumab celmoleukin from EMD Lexigen is a fusion protein in Phase II (978) 294-1100

volociximab from PDL BioPharma is a monoclonal antibody in Phase II (510) 574-1400

There are others and I will post on those from time to time as they come across my research desk.